Bronchial Cryo-Denervation for Severe Asthma: A Pilot Study

Area of Science:

• Pulmonology
• Interventional Pulmonology
• Respiratory Medicine

Background:

• Pharmacologic targeting of the parasympathetic nervous system improves severe asthma outcomes.
• Bronchial cryo-denervation (BCD) is an emerging non-pharmacologic therapy using cryo-ablation to denervate pulmonary parasympathetic nerves.

Purpose of the Study:

• To evaluate the safety, technical feasibility, and initial efficacy of BCD in patients with severe asthma.

Main Methods:

• A prospective, single-center pilot study enrolled 15 severe asthma patients.
• Patients received bifurcated BCD treatment via bronchoscopy, with follow-up for 12 months.
• Assessments included adverse events, pulmonary function, Asthma Control Questionnaire-7 (ACQ-7), and Asthma Control Test (ACT).

Main Results:

• BCD demonstrated 96.7% technical feasibility with a favorable safety profile; 2 serious adverse events resolved without sequelae.
• No significant changes in pulmonary function were observed.
• Significant improvements in ACQ-7 and ACT scores were noted from 1 month post-treatment through 12 months.

Conclusions:

• This study presents the first clinical evidence supporting the safety, feasibility, and initial efficacy of BCD for severe asthma.
• BCD offers a potential new therapeutic option for patients with severe, refractory asthma.